Protocol
Structured exercise program after treatment for non-metastatic cancer
In people who have finished treatment for cancer, randomized trials of structured exercise programs show longer disease-free and overall survival.
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The protocol said it covered early-stage cancer. Its deciding trial, CHALLENGE (Courneya et al., N Engl J Med, 2025; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 40450658), enrolled people with resected high-risk stage II or stage III colon cancer, which readers would not call early-stage. The scope now reads non-metastatic cancer, which is what the trials and the pooled analysis covered. The letter is unchanged.PMID 40450658
A new graded protocol covers structured exercise programs after treatment for early-stage cancer, graded on disease-free and overall survival. CHALLENGE (Courneya et al., N Engl J Med, 2025; PMID 40450658) randomized 889 people after colon cancer chemotherapy and found 5-year disease-free survival of 80.3 against 73.9 percent. A 2026 meta-analysis A study that pools the numbers from several trials into one combined estimate. of 21 randomized trials (Tzang et al., Br J Sports Med; PMID 42744658) found the same direction across cancer types. Graded B rather than A because the pooled trials are mostly in breast cancer and in colon cancer the result rests on one trial. CHALLENGE was also added to the landmark trials library.PMID 40450658 PMID 42744658
Every change to a letter on this site is dated and published. The full evidence log →
This is a structured exercise program for people who have finished treatment for cancer that has not spread. In the largest trial, 889 people treated for colon cancer joined a 3-year supported exercise program or got health reading materials. Those in the program stayed free of cancer longer and lived longer. A review of 21 trials, mostly in women with breast cancer, found the same direction. The program came after standard cancer care, not in place of it. Muscle and joint problems were more common in the exercise group.
In people who have finished treatment for cancer, randomized trials of structured exercise programs show longer disease-free and overall survival. The strongest single trial is CHALLENGE (Courneya et al., N Engl J Med, 2025; PMID 40450658): 889 people with resected high-risk stage II or stage III colon cancer, enrolled 2 to 6 months after completing adjuvant chemotherapy, were assigned to a 3-year program of behavioral support and supervised exercise sessions or to health-education materials alone (design: Courneya et al., Curr Oncol, 2008; PMID 19079628). At a median follow-up of 7.9 years, 5-year disease-free survival was 80.3 percent against 73.9 percent, an absolute difference of 6.4 percentage points (hazard ratio How often an event happened in the treated group compared with the control group over the same period. A ratio of 0.80 means 20 percent fewer events. for recurrence, a new primary cancer or death 0.72, 95% CI 0.55 to 0.94). Eight-year overall survival was 90.3 percent against 83.2 percent (hazard ratio for death 0.63, 95% CI 0.43 to 0.94), a secondary endpoint An outcome a trial also measures but did not choose as its main test. the authors describe as consistent with longer survival. A 2026 meta-analysis of 21 randomized trials (Tzang et al., Br J Sports Med; PMID 42744658), 8,449 participants, 88 percent of them women and breast cancer the most studied type, pooled overall survival at hazard ratio 0.77 (95% CI 0.65 to 0.92, 11 trials) and disease-free survival at 0.83 (95% CI 0.72 to 0.95, 7 trials), certainty rated moderate; progression-free survival and pathological complete response did not improve. In CHALLENGE the comparison was a supported, supervised program against written health education, not exercise against none. The program followed standard cancer treatment and did not replace any part of it.
Why this gradeThe reasoning, and what the grade does not cover.
Grade B on disease-free and overall survival, both hard clinical endpoints An outcome that matters directly to a person and is counted without judgment, such as death, heart attack, stroke or fracture.. A large randomized trial designed with disease-free survival as its primary endpoint The one outcome a trial names in advance as its main test. Results on other outcomes carry less weight. met it (CHALLENGE, PMID 40450658), and a meta-analysis of 21 randomized trials found the same direction for overall and disease-free survival (PMID 42744658). Not A: the Grade A definition requires the effect to repeat across independent research groups in the population graded. The pooled trials mix cancer types, most participants had breast cancer, the review's authors rate the certainty moderate, and in colon cancer the result rests on CHALLENGE alone, which Rule 03 does not count as replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. however large it is. Not C because the survival effect does not stand on one trial: further randomized trials point the same way. The grade covers structured programs after curative-intent treatment for non-metastatic cancer.
WHAT THIS GRADE DOES NOT COVERadvanced or metastatic disease, where the review found little evidence; cancer prevention in people who have never had cancer, which these trials did not test; and exercise in place of surgery, chemotherapy or radiation, which no trial tested.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Musculoskeletal adverse events were more frequent in the exercise group in CHALLENGE, 18.5 against 11.5 percent of patients. The trial program included supervised sessions.
The evidence, in fullThree papers, each linked to its PubMed record.
Courneya et al. (N Engl J Med, 2025; PMID 40450658), CHALLENGE: phase 3 randomized trial at 55 centers, 889 patients with resected colon cancer who had completed adjuvant chemotherapy; 3-year structured exercise program against health-education materials; 5-year disease-free survival 80.3 against 73.9 percent (hazard ratio 0.72, 95% CI 0.55 to 0.94, p=0.02); 8-year overall survival 90.3 against 83.2 percent (hazard ratio 0.63, 95% CI 0.43 to 0.94); musculoskeletal adverse events 18.5 against 11.5 percent; funded by the Canadian Cancer Society and others. Tzang et al. (Br J Sports Med, 2026; PMID 42744658): systematic review A review that searches for every study on a question using a method set in advance, then assesses them together. and meta-analysis of 21 randomized trials of structured exercise in adults with cancer; overall survival hazard ratio 0.77 (95% CI 0.65 to 0.92, 11 trials, n=3,828), disease-free survival 0.83 (95% CI 0.72 to 0.95, 7 trials, n=5,077), all-cause mortality risk ratio 0.82, cancer-specific mortality risk ratio 0.74; no effect on progression-free survival or pathological complete response; GRADE certainty moderate; competing interests none declared. Courneya et al. (Curr Oncol, 2008; PMID 19079628): CHALLENGE design paper; high-risk stage II or stage III colon cancer, adjuvant therapy completed within the previous 2 to 6 months, behavioral support program and supervised sessions over 3 years, primary endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. disease-free survival.
Measured outcome in the trials: disease-free survival (recurrence, a new primary cancer or death) and overall survival, followed for a median of 7.9 years in CHALLENGE.
Evidence notes: randomized trial, meta-analysis
Endpoint graded: Disease-free survival and overall survival after curative-intent treatment for non-metastatic cancer, structured exercise program against health education or usual care (hard)
Last reviewed: October 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
As studiedDose, form, population and duration for every use.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
(exercise[tiab] OR "physical activity"[tiab]) AND (cancer[tiab] OR neoplasms[mh]) AND ("disease-free survival"[tiab] OR "overall survival"[tiab] OR "cancer recurrence"[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt])Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →